First Wave BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- First Wave BioPharma's estimated annual revenue is currently $2.3M per year.
- First Wave BioPharma's estimated revenue per employee is $155,000
Employee Data
- First Wave BioPharma has 15 Employees.
- First Wave BioPharma grew their employee count by 0% last year.
First Wave BioPharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Product Development | Reveal Email/Phone |
2 | Head Laboratory | Reveal Email/Phone |
3 | VP for Translational Research | Reveal Email/Phone |
4 | SVP Corporate Development | Reveal Email/Phone |
5 | Director Human Resources | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Product Development Manager | Reveal Email/Phone |
9 | Chairman | Reveal Email/Phone |
10 | Operations Assistant | Reveal Email/Phone |
First Wave BioPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is First Wave BioPharma?
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI clinical programs. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
First Wave BioPharma News
First Wave BioPharma, Inc. (NASDAQ:FWBI) Short Interest Up 72.1% in March. Posted by admin on Apr 16th, 2022. Share on Twitter Share on Facebook Share on...
First Wave BioPharma (NASDAQ: FWBI, $FWBI), a clinical-stage biopharmaceutical company specializing in developing targeted, non-systemic...
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for...